Alan Carlson, MD
Hematology · Durham, NCNPI 1124181995
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,701 of the $143,139 with a category attached, or 99.0%. Johnson & Johnson Surgical Vision, Inc. accounts for 99.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $141,915 and has fallen 99.5% since, to $678 in 2024.
Across 20 payments — averaging $7156.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$142K
- Biotissue Holdings Inc.$503
- Sun Pharmaceutical Industries Inc.$271
- Quidel Corporation$214
- Oyster Point Pharma, Inc.$125
- Novartis$100
- plus $50 from 1 others
What the payments were for
- Speaking & faculty fees$141,70199%
- Food & beverage$1,4381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 4 | $141,876 |
| Biotissue Holdings Inc. | 8 | $503 |
| Sun Pharmaceutical Industries Inc. | 3 | $271 |
| Quidel Corporation | 1 | $214 |
| Oyster Point Pharma, Inc. | 1 | $125 |
| Novartis | 1 | $100 |
| Sight Sciences, Inc. | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eye Health$641
- CEQUA$144
- TYRVAYA$125
- Tecnis Simplicity$125
- XIIDRA$100
How this compares
$143,139 in reported general payments places this provider in the 80th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $14,827 |
| Loteprednol Etabonate | 55 | $7,962 |
| Fluorometholone | 49 | $4,932 |
| Prednisolone Acetate | 156 | $4,604 |
| ValacyclovirValacyclovir Hcl | 38 | $2,484 |
| Azithromycin | 162 | $832 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 14 | $717 |
| Dexamethasone Sodium Phosphate | 13 | $493 |
| ErythromycinErythromycin Base | 20 | $234 |
Paid to pharmacies, not to this prescriber.
Other hematology in Durham
- Lindsay ReinDurham$73K
- Jadee NeffDurham$71K
- Thomas OrtelDurham$61K
- Gowthami ArepallyDurham$37K
- Sascha TuchmanDurham$25K
- Oluwatoyosi OnwuemeneDurham$19K
- Andrew PeseskiDurham$371
- Charity OyedejiDurham$125
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.